BBIO BridgeBio Pharma Inc

Price (delayed)

$67.19

Market cap

$13.16B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.73

Enterprise value

$14.77B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 26

BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in ...

Highlights
BridgeBio Pharma's revenue has increased by 16% from the previous quarter
The gross profit has grown by 15% from the previous quarter
BridgeBio Pharma's quick ratio has plunged by 68% YoY and by 44% from the previous quarter
BBIO's equity is down by 38% year-on-year and by 9% since the previous quarter

Key stats

What are the main financial stats of BBIO

BBIO stock price

How has the BridgeBio Pharma stock price performed over time
Intraday
2.61%
1 week
-1.84%
1 month
-2.61%
1 year
76.72%
YTD
-12.16%
QTD
-9.52%

Financial performance

How have BridgeBio Pharma's revenue and profit performed over time
Revenue
$579.96M
Gross profit
$551.7M
Operating income
-$525M
Net income
-$721.55M
Gross margin
95.1%
Net margin
-124.4%
BBIO's operating margin has soared by 83% YoY and by 13% QoQ
BBIO's net margin has surged by 76% year-on-year and by 14% since the previous quarter
BBIO's operating income is up by 25% year-on-year
BridgeBio Pharma's revenue has increased by 16% from the previous quarter

Price vs fundamentals

How does BBIO's price correlate with its fundamentals

Growth

What is BridgeBio Pharma's growth rate over time

Valuation

What is BridgeBio Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
22.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.47
BBIO's EPS is down by 5% year-on-year
BBIO's equity is down by 38% year-on-year and by 9% since the previous quarter
The stock's price to sales (P/S) is 81% less than its 5-year quarterly average of 115.4 and 25% less than its last 4 quarters average of 29.3
BridgeBio Pharma's revenue has increased by 16% from the previous quarter

Efficiency

How efficient is BridgeBio Pharma business performance
BBIO's ROS has soared by 76% year-on-year and by 17% since the previous quarter
The ROA has grown by 20% YoY and by 12% from the previous quarter
The ROIC has contracted by 11% YoY

Dividends

What is BBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BBIO.

Financial health

How did BridgeBio Pharma financials performed over time
BBIO's total assets is 62% smaller than its total liabilities
BridgeBio Pharma's quick ratio has plunged by 68% YoY and by 44% from the previous quarter
The current ratio has shrunk by 67% YoY and by 45% QoQ
BBIO's equity is down by 38% year-on-year and by 9% since the previous quarter
BBIO's debt is up by 34% since the previous quarter and by 6% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.